Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab randomized withdrawal study in PAPA syndrome
2024-517155-13-00Phase 3Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in infectious arthritis (SA) comparing Canakinumab continuation with Placebo withdrawal arm (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
canakinumab
03
Conditions
infectious arthritis (SA)
Beyond the preview
Go deeper on 2024-517155-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517155-13-00.